FDA panel to discuss Neurocrine's Ingrezza

Neurocrine Biosciences Inc. (NASDAQ:NBIX) said FDA's Psychopharmacologic Drugs Advisory Committee will meet on Feb. 16, 2017, to discuss the company's NDA for Ingrezza valbenazine to treat tardive dyskinesia. The NDA is under Priority Review with a PDUFA date of April 11, 2017 (see BioCentury Extra, Oct. 11).

The selective vesicular monoamine transporter 2 (VMAT2; SLC18A2) inhibitor has breakthrough therapy designation for the indication...